Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.
Open Access
- 15 June 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 144 (12) , 4898-4905
- https://doi.org/10.4049/jimmunol.144.12.4898
Abstract
Recent studies have subdivided the Th cells into mutually exclusive Th1 subset producing IL-2 and IFN-gamma and Th2 cells producing IL-4 and IL-5. The relative role played by these two subsets in the antitumor immunity is not clear. We earlier demonstrated that treatment of C57BL/6 mice bearing a syngeneic Ia- T cell lymphoma, LSA, with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) resulted in 90 to 100% survival of the mice. Furthermore, host's T cell responses were critical for successful BCNU-mediated cures. In our study we observed that immediately after BCNU treatment, there was a dramatic increase in the percentage of CD4+ T cells at the site of tumor growth in the peritoneal cavity. The percentage of CD4+ T cells increased from approximately 3 to 4% found in normal or tumor-bearing mice to approximately 41% in BCNU-treated tumor-bearing mice. The percentage of CD8+ T cells also increased although to a lesser degree. Also, these alterations were primarily restricted to the site of tumor-growth inasmuch as they were not seen in the thymus and were less pronounced in the spleen. The tumor-infiltrating CD4+ T cells obtained after BCNU-treatment, when further characterized, were found to secrete only IL-2 and IFN-gamma but not IL-4, after tumor-specific stimulation. Furthermore, the supernatants from LSA-activated CD4+ T cell cultures failed to provide help to the B cells but were able to activate the macrophages to inhibit the tumor cell proliferation. The CD4+ T cells when adoptively transferred could also protect the nude mice from LSA tumor challenge and induced tumor-specific delayed-type hypersensitivity reaction. Together our data suggest that in the LSA tumor model, the tumor-infiltrating CD4+ T cells have the properties of Th1 cells and these cells can mediate tumor-rejection independent of the CD8+ T cells by activating the macrophages.This publication has 19 references indexed in Scilit:
- B cell stimulatory factor 1 (interleukin 4) is sufficient for the proliferation and differentiation of lectin-stimulated cytolytic T lymphocyte precursors.The Journal of Experimental Medicine, 1987
- Inhibition of B lymphocyte activation by interferon-gamma.The Journal of Immunology, 1987
- Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones.The Journal of Immunology, 1987
- The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.The Journal of Immunology, 1985
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.The Journal of Experimental Medicine, 1985
- Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.The Journal of Immunology, 1985
- Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors.The Journal of Immunology, 1985
- Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor.Proceedings of the National Academy of Sciences, 1984
- Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells.The Journal of Experimental Medicine, 1983
- Macrophage activation: dissociation of cytotoxic activity from Ia-A antigen expression.Proceedings of the National Academy of Sciences, 1983